The LCBRN collects tissue and biofluids from consented patients undergoing surgical resection for known or suspected lung cancer. After a patient is consented for the LCBRN study, baseline fluids (saliva, serum, plasma, urine) are collected pre-operatively. The LCBRN also obtains baseline fluids from advanced stage lung cancer patients who are not candidates for resection but who require an operation for staging and/or diagnostic procedures.
|Fluid Types||Fluid Attributes|
Buffy coat from plasma
Bronchial lavage cell pellet
No known cancer
Pre-op, with cancer
Post-op, no known cancer
Post-op, with known cancer recurrence
Late stage cancer, pre-treatment
Late stage cancer, post-treatment
For subjects who are eligible for surgery, both bronchial washings and tissue are obtained intra-operatively. Tissue is procured following clinical assessment by a pathologist to determine if “left over” remnant tissue is available for research procurement.
|Tissue Types Available|
Non-neoplastic lung from non-cancer patients
|DNA, RNA and Protein Extracts* Available|
*DNA and RNA are available as 10 uL aliquots of 100-150 ng/uL concentration. The RNA isolation procedures obtain low molecular weight (miRNA, etc. – see figure below) as well as high molecular weight species. Protein extracts are split TCA precipitates from approximately 100 mg tissue samples. See SOP #14 and SOP#15.
After surgery, LCBRN subjects are followed up at sequential 6-month intervals during which biofluids are again obtained. Clinical data is still obtained from any subjects who are unable to return for follow-up specimen collection.
|Summary of Procurement Events|
Baseline collection (pre-op): serum, plasma, urine, saliva
Surgical procedure (intra-op): tissue, bronchial lavage fluid
1st follow-up visit (post-op): serum, plasma, urine, saliva
Subsequent follow-up visits (post-op): serum, plasma, urine